Developing a new treatment to improve outcomes for melanoma patients
Development of a small-molecule immunomodulator for the treatment of melanoma
This study is testing a new treatment called 15dPMJ2 to see if it can make existing melanoma therapies work better by helping the immune system fight the cancer, and it's aimed at patients with advanced melanoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Claradele Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Winterville, United States) |
| Project ID | NIH-10379630 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of existing melanoma treatments by using a novel small-molecule immunomodulator called 15dPMJ2. The approach involves pretreating melanoma lesions with this compound to increase their sensitivity to PD1 blockade therapy, which is a common immunotherapy for melanoma. The study will determine the optimal safe doses of 15dPMJ2 to be used alongside anti-PD1 treatments and assess its ability to promote tumor inflammation and immune cell infiltration in the tumors. This could lead to improved treatment responses for patients with advanced melanoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced melanoma who have not responded to current immunotherapies or have developed resistance to existing treatments.
Not a fit: Patients with early-stage melanoma or those who have not yet undergone immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and treatment options for patients with advanced melanoma.
How similar studies have performed: Other research has shown promising results with similar immunomodulatory approaches, indicating potential for success in this area.
Where this research is happening
Winterville, United States
- Claradele Pharmaceuticals, INC. — Winterville, United States (Active)
Researchers
- Principal investigator: Van Dross, Rukiyah — Claradele Pharmaceuticals, INC.
- Study coordinator: Van Dross, Rukiyah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.